ProPhase completes $4.5M tender offer

ProPhase Labs Inc. is buying back $4.5 million of its common stock, completing a tender offer announced earlier this month. The Doylestown, Pa., natural health products company said Thursday it has accepted for purchase about 1.95 million shares at $2.30 per share. That number of shares represents about 15 percent of the 12.4 million shares of ProPhase (NASDAQ:PRPG) common stock that have been issued by the company. ProPhase is the original developer of Cold-Eeze zinc lozenges for cold suffers.…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
More News: Health Management | Zinc